BCAAs in Concussion 2.0

Last updated: June 11, 2025
Sponsor: Akiva Cohen
Overall Status: Active - Recruiting

Phase

2

Condition

Brain Injury

Treatment

BCAA

Placebo

Clinical Study ID

NCT06829498
23-021206
  • Ages 11-23
  • All Genders

Study Summary

This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAAs) in the treatment of concussion. The aim of the study is to determine whether administration of high-dose BCAAs compared to placebo promotes concussion recovery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Males and females,11 - 23 years of age.

  2. Weigh at least 40kg.

  3. Meeting concussion criteria for the American Congress of Rehabilitative Medicine.

  4. Present within 4 days of injury.

  5. Post-menarchal females must have a negative urine pregnancy test and must use anacceptable method of contraception.

  6. Informed consent by the participant, or for participants <18 years old both informedconsent by a parent/guardian and child assent.

Exclusion

Exclusion Criteria:

  1. Evidence of moderate or severe Traumatic Brain Injury (TBI), including Glasgow ComaScale (GCS) <13, TBI requiring hospital admission, or TBI requiring neurosurgicalintervention.

  2. Prior concussion or TBI within 90 days.

  3. Known history of maple syrup urine disease or known family history of maple syrupurine disease.

  4. Any investigational drug use within 30 days prior to enrollment.

  5. Hypersensitivity to any ingredient in the active or placebo products.

  6. Participants who are pregnant, planning on becoming pregnant during the studyduration, or breastfeeding.

  7. Non-English speaking participants or parent/guardian.

Study Design

Total Participants: 150
Treatment Group(s): 2
Primary Treatment: BCAA
Phase: 2
Study Start date:
April 01, 2025
Estimated Completion Date:
August 31, 2026

Study Description

Annually, approximately 2 million concussions occur in the pediatric and young adult population. Approximately 30% of those diagnosed with concussion will experience persisting symptoms lasting beyond 28 days. Concussion is a heterogeneous injury to the brain that precipitates a complex pathophysiological process that can result in a cascade of deleterious side effects. At present, there are no targeted therapeutics that can mitigate or prevent the deleterious effects of concussion. In preclinical, analysis of ipsilateral hippocampi isolated from mice after traumatic brain injury (TBI) demonstrated that only the concentrations of the three branched chain amino acids (BCAAs) (valine, isoleucine, and leucine) were significantly reduced after injury. When these brain-injured animals received dietary supplementation with BCAAs, the concentrations of these amino acids were restored in the injured hippocampus and the injured animals demonstrated significant cognitive improvement to levels comparable to those obtained in non-injured control animals. The pilot study (NCT01860404) provides evidence of BCAAs in concussed adolescents and young adults providing a dose-response effect in reducing concussion symptoms and a return to baseline physical activity in those treated with higher total doses of BCAAs, warranting this larger trial to inform clinical practice around BCAA treatment in concussion.

Connect with a study center

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania 19146
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.